Clinical Trial Update: SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing the safety of activated prothrombin complex concentrate after emicizumab prophylaxis in people with Hemophilia A; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• FEIBA (activated prothrombin complex concentrate)
• Hemlibra (emicizumab)

Snippet

Sponsor: Emory University | Conditions: Hemophilia A | Phase 3 | Status: RECRUITING